Catabasis Pharma (CATB): Preview of Edasalonexent Proof-Of-Concept Study - Wedbush
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Wedbush analyst, Heather Behanna, reiterated her Outperform rating on shares of Catabasis Pharma (NASDAQ: CATB) and her price target of $17 representing more than a 4x return on investment. The MoveDMD proof-of-concept study enrollment is complete and the analyst expects data in the first six weeks of 1Q17.
The analyst believes the science behind Catabasis’s NF-kB inhibitor, edasalonexent (CAT-1004), is sound and recent data from the World Muscle Society (WMS) suggests the compound is knocking down NF-kB in DMD boys. The analyst sees a compelling risk/reward for edasalonexent, with a best case scenario of a significant benefit (as measured by MR) at three months.
Boys will continue to be studied through a year to see functional changes and the analyst believes the six-month data can drive pivotal trial design and allow a greater time window for the benefit to be observed.
Shares of Catabasis closed at $4.71 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Seaport Global Securities Starts Canadian Pacific Railway Limited (CP) at Buy
- H.C. Wainwright Downgrades Vertex (VRTX) to Neutral
- Cowen Upgrades Dick's Sporting Goods (DKS) to Outperform
Create E-mail Alert Related CategoriesAnalyst Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!